Jennifer Silva discusses important safety considerations when treating patients with Vitiligo using JAK inhibitors, emphasizing the need for clear patient counseling regarding black box warnings and potential risks associated with these therapies.
Her presentation highlights the role of informed discussions in helping patients understand treatment expectations, safety profiles, and the balance between therapeutic benefit and potential adverse effects.
Topics Covered
- Black box warnings associated with JAK inhibitors
- Safety considerations in vitiligo treatment planning
- Strategies for counseling patients about risks and benefits
- Supporting informed decision-making and treatment adherence
Explore Related Resources